Inchon, South Korea
VaxGen, developer of an AIDS vaccine soon to exit phase 3 trials, will be acquiring a manufacturing plant in South Korea through a partnership with Celltrion, a South Korean venture partnership. Based in Brisbane, Calif., VaxGen will trade knowledge of human protein manufacturing for use of a manufacturing facility in Inchon, Celltrion's hometown. VaxGen will hold a 44% stake in the partnership. Celltrion aims to produce other biotech products at the facility in addition to VaxGen's vaccine. Celltrion also plans to develop a research facility for VaxGen in South San Francisco.